B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SPTLC2

MOLECULAR TARGET

serine palmitoyltransferase long chain base subunit 2

UniProt: O15270NCBI Gene: 95171 compounds

SPTLC2 (serine palmitoyltransferase long chain base subunit 2) is targeted by 1 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SPTLC2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1myriocin1.102

About SPTLC2 as a Drug Target

SPTLC2 (serine palmitoyltransferase long chain base subunit 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 1 compounds with documented SPTLC2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SPTLC2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.